Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Dec;18(6):959–962. doi: 10.1111/j.1365-2125.1984.tb02571.x

Domperidone and levodopa in Parkinson's disease.

J S Shindler, G T Finnerty, K Towlson, A L Dolan, C L Davies, J D Parkes
PMCID: PMC1463696  PMID: 6529536

Abstract

To study the absorption of levodopa and interaction with the extracerebral dopamine antagonist domperidone, 15 patients with idiopathic Parkinson's disease were given levodopa 500 mg p.o., alone, and with domperidone pre-treatment. Domperidone pretreatment (10, 20, 40 mg, p.o., i.v. or i.m.) caused a mean 12% increase in peak plasma levodopa concentration, which occurred a mean of 10 min earlier than when levodopa was given alone. Parkinsonian disability scores were improved and peak clinical response occurred 16 min earlier with domperidone than without. Domperidone slightly increases the immediate bioavailability (over 4 h) and anti-parkinsonian response to a given dose of levodopa.

Full text

PDF
959

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bianchine J. R., Calimlim L. R., Morgan J. P., Dujuvne C. A., Lasagna L. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease. Ann N Y Acad Sci. 1971 Jul 6;179:126–140. doi: 10.1111/j.1749-6632.1971.tb46895.x. [DOI] [PubMed] [Google Scholar]
  2. Fermaglich J., O'Doherty D. S. Effect of gastric motility on levodopa. Dis Nerv Syst. 1972 Sep;33(9):624–625. [PubMed] [Google Scholar]
  3. Freed C. R., Asmus P. A. Brain tissue and plasma assay of L-DOPA and alpha-methyldopa metabolites by high performance liquid chromatography with electrochemical detection. J Neurochem. 1979 Jan;32(1):163–168. doi: 10.1111/j.1471-4159.1979.tb04523.x. [DOI] [PubMed] [Google Scholar]
  4. Gundert-Remy U., Hildebrandt R., Stiehl A., Weber E., Zürcher G., Da Prada M. Intestinal absorption of levodopa in man. Eur J Clin Pharmacol. 1983;25(1):69–72. doi: 10.1007/BF00544017. [DOI] [PubMed] [Google Scholar]
  5. Laduron P. M., Leysen J. E. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979 Jul 15;28(14):2161–2165. doi: 10.1016/0006-2952(79)90198-9. [DOI] [PubMed] [Google Scholar]
  6. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  7. Mearrick P. T., Wade D. N., Birkett D. J., Morris J. Metoclopramide, gastric emptying and L-dopa absorption. Aust N Z J Med. 1974 Apr;4(2):144–148. doi: 10.1111/j.1445-5994.1974.tb03163.x. [DOI] [PubMed] [Google Scholar]
  8. Miller R. Metoclopramide and dopamine receptor blockade. Neuropharmacology. 1976 Aug;15(8):463–469. doi: 10.1016/0028-3908(76)90056-3. [DOI] [PubMed] [Google Scholar]
  9. Morgan J. P., Rivera-Calimlim L., Messiha F., Sundaresan P. R., Trabert N. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology. 1975 Nov;25(11):1029–1034. doi: 10.1212/wnl.25.11.1029. [DOI] [PubMed] [Google Scholar]
  10. Nutt J. G., Woodward W. R., Hammerstad J. P., Carter J. H., Anderson J. L. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med. 1984 Feb 23;310(8):483–488. doi: 10.1056/NEJM198402233100802. [DOI] [PubMed] [Google Scholar]
  11. Parkes J. D. Adverse effects of antiparkinsonian drugs. Drugs. 1981 May;21(5):341–353. doi: 10.2165/00003495-198121050-00002. [DOI] [PubMed] [Google Scholar]
  12. Rivera-Calimlim L., Dujovne C. A., Morgan J. P., Lasagna L., Bianchine J. R. L-dopa treatment failure: explanation and correction. Br Med J. 1970 Oct 10;4(5727):93–94. doi: 10.1136/bmj.4.5727.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schachter M., Bédard P., Debono A. G., Jenner P., Marsden C. D., Price P., Parkes J. D., Keenan J., Smith B., Rosenthaler J. The role of D-1 and D-2 receptors. Nature. 1980 Jul 10;286(5769):157–159. doi: 10.1038/286157a0. [DOI] [PubMed] [Google Scholar]
  14. Schuurkes J. A., Van Nueten J. M. Is dopamine an inhibitory modulator of gastrointestinal motility? Scand J Gastroenterol Suppl. 1981;67:33–36. [PubMed] [Google Scholar]
  15. Van Nueten J. M., Ennis C., Helsen L., Laduron P. M., Janssen P. A. Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone. Life Sci. 1978 Aug 7;23(5):453–457. doi: 10.1016/0024-3205(78)90152-2. [DOI] [PubMed] [Google Scholar]
  16. Wade D. N., Mearrick P. T., Birkett D. J., Morris J. Variability of L-dopa absorption in man. Aust N Z J Med. 1974 Apr;4(2):138–143. doi: 10.1111/j.1445-5994.1974.tb03162.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES